Advertisement

Topics

FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib

07:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
FASLODEX in Combination with Abemaciclib Showed 16.4 Months of Progression-Free Survival (PFS) Second Approval in Three Months Expands Treatment Options for Women with HR+, HER2- Advanced Breast Cancer AstraZ...

Other Sources for this Article

Media Inquiries
For AstraZeneca:
Michele Meixell, +1 302-885-2677
or
Stephanie Wiswall, +1 302-885-2677

NEXT ARTICLE

More From BioPortfolio on "FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...